Ontology highlight
ABSTRACT: Objective
This study aimed to retrospectively assess the efficacy and safety of anagrelide in cytoreduction therapy-naïve essential thrombocythemia (ET) patients in a real-world setting.Method
Data from 53 ET patients who received anagrelide as a first-line therapy were reviewed for patient characteristics, antiplatelet status, cytoreduction status, therapeutic effects, adverse events, thrombohemorrhagic event development, progression to myelofibrosis or acute leukemia, and cause of death.Results
The rate of achieving a platelet count of <600 × 109 /L during anagrelide monotherapy was 83.0%. Adverse events occurred in 32 of 53 patients, and tended to be slightly more severe in patients with cardiac failure; however, they were mostly tolerable. The therapeutic effect of anagrelide was consistent, regardless of genetic mutation profiles. The incidence of anemia as an adverse event was significantly higher in the CALR mutation-positive group. Favorable platelet counts were also achieved in patients for whom hydroxyurea was introduced as a replacement for anagrelide or in addition to anagrelide because of unresponsiveness or intolerance to treatment.Conclusion
In Japanese cytoreduction therapy-naïve ET patients, anagrelide administration as a first-line therapy demonstrated favorable effects in reducing platelet counts, and its safety profile that was generally consistent with those in previous reports.
SUBMITTER: Ito T
PROVIDER: S-EPMC6851998 | biostudies-literature | 2019 Aug
REPOSITORIES: biostudies-literature
Ito Tomoki T Hashimoto Yoshinori Y Tanaka Yasuhiro Y Nakaya Aya A Fujita Shinya S Satake Atsushi A Nakanishi Takahisa T Konishi Akiko A Hotta Masaaki M Yoshimura Hideaki H Ishii Kazuyoshi K Hashimoto Akiko A Kondo Toshinori T Omura Hiromi H Shinzato Isaku I Tanaka Takayuki T Nomura Shosaku S
European journal of haematology 20190617 2
<h4>Objective</h4>This study aimed to retrospectively assess the efficacy and safety of anagrelide in cytoreduction therapy-naïve essential thrombocythemia (ET) patients in a real-world setting.<h4>Method</h4>Data from 53 ET patients who received anagrelide as a first-line therapy were reviewed for patient characteristics, antiplatelet status, cytoreduction status, therapeutic effects, adverse events, thrombohemorrhagic event development, progression to myelofibrosis or acute leukemia, and cause ...[more]